EDGAR Filing Documents for 0001193125-09-228977

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:

SEC Accession No. 0001193125-09-228977

Filing Date

2009-11-09

Accepted

2009-11-09 13:08:24

Documents

Period of Report

2009-09-30

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 10-Q	d10q.htm	10-Q	597541
2	RESEARCH COLLABORATION TERMINATION AGREEMENT, DATED AS OF JULY 29, 2009	dex10323.htm	EX-10.323	25663
3	AMENDMENT NO. 2 TO PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT	dex10331.htm	EX-10.331	25123
4	SECTION 302 CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER	dex311.htm	EX-31.1	6632
5	SECTION 302 CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER	dex312.htm	EX-31.2	6695
6	SECTION 906 CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER	dex321.htm	EX-32.1	4512
7	SECTION 906 CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER	dex322.htm	EX-32.2	4376
	Complete submission text file	0001193125-09-228977.txt		671956

Mailing Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117

Business Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117 858-550-7500

LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)